|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing and Reimbursement - Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies
GBI Research, Feb 2010, Pages: 83
“Pharmaceutical Pricing and Reimbursement - Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies” provides key data, information and analysis of the major issues affecting the pricing and reimbursement decisions across the globe. It discusses the major changes that have been observed in the pharmaceutical and healthcare industry at the global level. The report also covers issues specific to particular geographies. The geographies covered include the US and countries within Western Europe, Asia-Pacific, Central and Eastern Europe, and Scandinavia. It covers pricing and reimbursement mechanisms in different countries as well as the impact of issues on the key stakeholders. The report puts a special emphasis on orphan drugs since the pricing and reimbursement patterns for orphan drugs are different from the traditional mechanisms.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
Scope
The scope of this report includes:
- Identification and analysis of major issues that are affecting the pricing and reimbursement decisions across five different geographies. These include North America, Western Europe, Asia-Pacific, Central and Eastern Europe and Scandinavia
- Analysis of the issues and potential impact of pricing and reimbursement decisions on the key stakeholders
- Study of the pricing and reimbursement mechanisms in different countries and the identification of trends in the context of a particular geography as a whole
- Qualitative analysis of the forces that are driving and restraining the prices and reimbursements within a particular geography
- Future outlook of the pricing and reimbursement patterns for geographies under consideration
Reasons to buy
The report will enhance your decision making and will enable you to:
- Build understanding of the major issues in the pricing and reimbursement landscape
- Identify the impact of each issue on your business and develop solutions for adverse impacts
- Negotiate better with the government agencies to maximize the reimbursement on the drugs by understanding the pricing and reimbursement mechanism
- Develop effective business strategies for pricing a drug which is to be launched in any of the markets considered in this report
- Identify and exploit the factors that could help to maximize returns on the drugs for a particular geography in future
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies
Pharma Pricing and Reimbursement Outlook: Optimizing Price and Market Access in a Recessionary Climate
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs
Pharmaceutical Pricing and Reimbursement: Strategies for Market Access Across the US, Europe, Japan and Other Key Geographies
Pharmacoeconomic Analysis in R&D Decision Making
Pricing and Reimbursement Risk and Opportunities in Pharmaceutical Deal Making
Market Access Korea - Breaking into the Developed World’s Fastest Growing Pharmaceutical Market
|
|
|
|
